Honeywell International Inc. (HON) reported first-quarter 2025 adjusted earnings of $2.51 per share, which surpassed the Zacks Consensus Estimate of $2.21. The bottom line increased 7% year over year on an adjusted basis. On a reported basis, the company’s earnings were $2.22 per share, flat year over year.Total revenues of $9.82 billion beat the consensus estimate of $9.57 billion. The top line increased 8% from the year-ago quarter, driven by strength in the Aerospace Technologies segment. Organic sales i ...

FIRST QUARTER 2025 EARNINGS RELEASE FORWARD LOOKING STATEMENTS We describe many of the trends and other factors that drive our business and future results in this presentation. Such discussions contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including statements related to the proposed spin-off of the Company's Advanced Materials business into Solstice Advanced Materials, a standalone, publicly traded company, the pr ...

Honeywell (HON) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Sean Meakim - VP - IRVimal Kapur - Chairman & CEOMike Stepniak - SVP & CFONigel Coe - Managing DirectorSteve Tusa - Managing DirectorAndrew Obin - Managing Director - Equity ResearchSheila Kahyaoglu - Managing DirectorAmit Mehrotra - Managing DirectorJoe Ritchie - Managing DirectorChris Snyder - Executive DirectorAndrew Kaplowitz - Managing Director Conference Call Participants Julian Mitchell - Equity Research AnalystScot ...

CHARLOTTE, N.C., April 29, 2025 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced results for the first quarter that exceeded the company's guidance on all metrics. The company also maintained its full-year organic growth guidance, raised its adjusted earnings per share guidance range, and reiterated its free cash flow guidance range. The company reported first-quarter year-over-year sales growth of 8% and organic1 sales growth of 4%, led by a second consecutive quarter of double-digit organic sales g ...

Core Viewpoint - Hillenbrand, Inc. has completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital for $287 million, aligning with its strategy to enhance margins by focusing on higher growth opportunities [1][4]. Group 1: Sale Details - The Milacron business was acquired by Hillenbrand in 2019 and contributed $526 million in revenues and $64 million in adjusted EBITDA in fiscal 2024 [2][3]. - Following the sale, Bain Capital owns approximately 51% of Milacron and has full operational control, while Hillenbrand retains a 49% stake [4]. Group 2: Financial Implications - Hillenbrand plans to use the net proceeds of approximately $250 million from the sale to repay its debt [4]. - The fiscal 2025 revenue outlook for Hillenbrand's remaining businesses has been updated to a range of $2.625 - $2.790 billion, down from the previous estimate of $2.925 - $3.090 billion [5]. - Total adjusted EBITDA is expected to be between $411 million and $447 million, with adjusted earnings per share anticipated in the range of $2.45 - $2.80 [6]. Group 3: Stock Performance - Hillenbrand's stock has experienced a significant decline, losing 50.5% over the past year, compared to an 11.4% decline in the industry [7].

Core Viewpoint - Hillenbrand, Inc. has completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital for $287 million, retaining a 49% ownership stake [1][2][3] Group 1: Transaction Details - Bain Capital now holds approximately 51% of Milacron and has full operational control, while Hillenbrand retains a 49% stake [2] - The transaction is expected to yield after-tax net proceeds of approximately $250 million for Hillenbrand, which will be used to pay down debt [4] Group 2: Strategic Implications - This sale reflects Hillenbrand's ongoing transformation into a pure-play industrial company, allowing it to focus on core process and automation equipment for food, pharmaceutical, and polymer markets [3] - The partnership with Bain Capital is anticipated to enhance Milacron's growth potential and operational success, leveraging Bain's resources and focus [4] Group 3: Historical Context - Hillenbrand acquired Milacron Holdings Corp. in 2019, which included Milacron's injection molding and extrusion business, along with Mold-Masters, DME, and Cimcool [3] - Hillenbrand previously sold the Cimcool business in 2020 and continues to own Mold-Masters and DME [3]